AVDL vs. ZLAB, KURA, TARO, SUPN, SDGR, DVAX, AKRO, HRMY, PTGX, and MORF
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Zai Lab (ZLAB), Kura Oncology (KURA), Taro Pharmaceutical Industries (TARO), Supernus Pharmaceuticals (SUPN), Schrödinger (SDGR), Dynavax Technologies (DVAX), Akero Therapeutics (AKRO), Harmony Biosciences (HRMY), Protagonist Therapeutics (PTGX), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
In the previous week, Avadel Pharmaceuticals had 7 more articles in the media than Zai Lab. MarketBeat recorded 16 mentions for Avadel Pharmaceuticals and 9 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.24 beat Avadel Pharmaceuticals' score of -0.27 indicating that Zai Lab is being referred to more favorably in the news media.
Avadel Pharmaceuticals received 110 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 65.22% of users gave Avadel Pharmaceuticals an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.
Avadel Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 4.0% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Avadel Pharmaceuticals has a net margin of 0.00% compared to Zai Lab's net margin of -125.46%. Zai Lab's return on equity of -37.07% beat Avadel Pharmaceuticals' return on equity.
Avadel Pharmaceuticals currently has a consensus target price of $24.17, suggesting a potential upside of 52.66%. Zai Lab has a consensus target price of $64.22, suggesting a potential upside of 205.68%. Given Zai Lab's higher possible upside, analysts clearly believe Zai Lab is more favorable than Avadel Pharmaceuticals.
Summary
Avadel Pharmaceuticals beats Zai Lab on 10 of the 17 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
